Objective: to assess persistence of sustained viral response at 5 years of follow-up in patients with chronic viral hepatitis C treated with pegylated interferon and ribavirin. Design: a descriptive study. Patients: from August 2001 to May 2004, all patients treated at our center with pegylated interferon and ribavirin who achieved a sustained viral response were consecutively enrolled (93 patients). Demographic, histological, biochemical, and virological data were collected during treatment and 5 years after achievement of the sustained viral response. Eighty-six percent of patients enrolled (n = 80) attended the control visit at 5 years. Results: mean age of enrolled patients was 41 years (standard deviation = 10 years), and 30.1% (n = 28) were women. Liver biopsy had been performed before treatment in 68.8% of patients (n = 64), showing no or mild fibrosis in 62.3% (F0 and F1) and significant fibrosis and cirrhosis in 37.7% (F ≥3). Genotype distribution was: 58.1% genotype 1 (n = 54); 8.6% genotype 2 (n = 8); 24.7% genotype 3 (n = 23); 7.5% genotype 4 (n = 7), and indeterminate in one patient. Only one patient experienced virological recurrence. All other patients had negative HCV RNA levels and, in the absence of other liver diseases, normal ALT levels. Conclusion: in patients treated with pegylated interferon and ribavirin with sustained viral response, long-term recurrence rate was very low. © 2011 ARÁN EDICIONES, S. L.
CITATION STYLE
Puig-del-Castillo, I., Miquel-Planas, M., Vergara-Gómez, M., Cebollero-Agustí, A., Gallach-Montero, M., Dalmau-Obrador, B., … Gavarró-Puig, A. (2011). Five-year follow-up of patients with chronic c hepatitis and sustained virological response. Revista Espanola de Enfermedades Digestivas, 103(2), 56–61. https://doi.org/10.4321/S1130-01082011000200002
Mendeley helps you to discover research relevant for your work.